Trius Therapeutics IncTSRX:NMQ

Add to portfolio
Set alert
Interactive chart
Historical prices
Data definitions
7.98
0.10 / 1.27%
731.87k
59.92%
0.00
Close in USDToday's changeShares traded1 year changeBeta
As of May 17 2013 21:00 BST.Data delayed by at least 15 minutes.
Overview
Balance sheet
Cash flow
Income statement

Income statement in USD

Year on year Trius Therapeutics Inc's revenues fell 33.71% from 41.01m to 27.19m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 18.25m to a larger loss of 53.93m. View full income statement

REVENUE
Gross margin--
Net profit margin-333.35%
Operating margin-327.76%
NET INCOME
Return on assets-64.78%
Return on equity-77.67%
Return on investment-77.67%

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped 105.75%.

EARNINGS PER SHARE
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-177.334

Cash flow in USD

In 2012, Trius Therapeutics Inc increased its cash reserves by 43.84%, or 4.99m. Cash Flow from Financing totalled 57.75m or 212.45% of revenues. In addition the company used 49.50m for operations while cash used for investing totalled 3.27m. View full cash flow statement

CASH FLOW
Cash flow per share-1.5429
Price/Cash flow per share--
CASH
Book value per share1.51
Tangible book value per share1.51

Balance sheet in USD

Trius Therapeutics Inc uses little or no debt in its capital structure. View full balance sheet

TOTAL ASSETS
Current ratio5.05
Quick ratio--
TOTAL DEBT
Total debt/total equity0.00
Total debt/total capital0.00
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.